Skip to search formSkip to main contentSkip to account menu

farletuzumab

Known as: Fareletuzumab 
A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (1)

Antibodies, Monoclonal, Humanized
FOLR1 protein, humanNCIt Antineoplastic Agent Terminologyantigen binding

Narrower (1)

MORAb-003

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Effect of the tumor-shed antigen CA125 on humoral immune responses of IgG1, IgG3, and IgM-type antibodies.
15Background: Human cancers employ a number of mechanisms to evade host immune responses. Here we report the effects of CA125 on… 
2017
2017
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
Cancers employ a number of mechanisms to evade host immune responses. Here we report the effects of tumor-shed antigen CA125… 
2016
2016
Analysis of molecular and protein signatures on farletuzumab pharmacokinetics from a phase 3 ovarian cancer study.
e14508Background: Farletuzumab (FAR) is a humanized monoclonal antibody that binds to folate receptor alpha which is highly… 
2016
2016
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated…
TPS5608Background: Farletuzumab (FAR) is a humanized monoclonal antibody that binds to folate receptor-alpha which is highly… 
Review
2016
Review
2016
Folate receptor targeted drug delivery- from the bench to the bedside
Targeted drug delivery is a promising strategy for improving tumor therapy. Folate receptor (FR) is an established ovarian cancer… 
Review
2013
Review
2013
Farletuzumab in lung cancer.
Review
2013
Review
2013
Although ovarian cancer may spread to distant sites via the bloodstream and / or nodal system , most of the Overview of Ovarian Cancer
Ovarian cancer is a relatively infrequent malignancy, but it is the fifth leading cause of cancer-related mortality in American… 
2011
2011
Farletuzumab, a monoclonal antibody against folate receptor alpha (FRα), does not block folate or anti-folate binding or alter drug potency assessed in vitro.
e13544 Background: FRα is overexpressed in a number of carcinomas. It is the target of the humanized monoclonal antibody… 
2010
2010
A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or…
TPS255 Background: Farletuzumab (MORAb-003) is a humanized monoclonal antibody that binds to the folate receptor alpha (FRA… 
2009
2009
8000 Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: preliminary data from a phase-2 study
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)